Publication Name	World Journal of Cardiology
Manuscript ID	74436
Country	United Kingdom

Received	2021-12-23 11:42
Peer-Review Started	2021-12-23 11:44
To Make the First Decision
Return for Revision	2022-02-15 00:57
Revised	2022-03-29 19:51
Second Decision	2022-06-15 02:59
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2022-06-18 03:08
Articles in Press	2022-06-18 03:08
Publication Fee Transferred
Edit the Manuscript by Language Editor	2022-06-22 17:04
Typeset the Manuscript	2022-07-15 05:40
Publish the Manuscript Online	2022-07-20 02:45

ISSN	1949-8462 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Retrospective Cohort Study
Article Title	Is there a window of opportunity to optimize trastuzumab cardiac monitoring?
Manuscript Source	Invited Manuscript
All Author List	Bruno Henrique Rala de Paula, Maria Eduarda Teixeira Ferro Costa, Carlos Augusto Moreira de Sousa and José Bines
Funding Agency and Grant Number
Corresponding Author	Bruno Henrique Rala de Paula, MD, MSc, Research Fellow, Sarah Cannon Research Institute, Sarah Cannon Research Institute, 93 Harley Street Central, London W1G 6AD, United Kingdom. brunobhrp@hotmail.com
Key Words	Cardiac toxicity; Ventricular Dysfunction; Heart failure; Trastuzumab; Breast cancer
Core Tip	It remains unclear whether the current arbitrary screening recommendations for trastuzumab related cardiotoxicity in early-stage HER2-positive breast cancer provides an adequate balance between preventing heart damage and curtailing a curative treatment. Real world data showed that despite a low rate of mainly early, asymptomatic and transient cardiotoxicity, treatment delays and interruptions occur due to these findings. The study results suggest optimization of cardiac monitoring after an initial period without a decrease in cardiac function.
Publish Date	2022-07-20 02:45
Citation	Rala de Paula BH, Costa METF, de Sousa CAM, Bines J. Is there a window of opportunity to optimize trastuzumab cardiac monitoring? World J Cardiol 2022; 14(7): 403-410
URL	https://www.wjgnet.com/1949-8462/full/v14/i7/403.htm
DOI	https://dx.doi.org/10.4330/wjc.v14.i7.403

Full Article (PDF)	WJC-14-403.pdf
Full Article (Word)	WJC-14-403.docx
Manuscript File	74436-Review-Filipodia.docx
Answering Reviewers	74436-Answering reviewers.pdf
Audio Core Tip	74436-Audio core tip.mp3
Biostatistics Review Certificate	74436-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form	74436-Conflict-of-interest statement.pdf
Copyright License Agreement	74436-Copyright license agreement.pdf
Signed Informed Consent Form(s) or Document(s)	74436-Informed consent statement.pdf
Institutional Review Board Approval Form or Document	74436-Institutional review board statement.pdf
Non-Native Speakers of English Editing Certificate	74436-Language certificate.pdf
Peer-review Report	74436-Peer-review(s).pdf
Scientific Misconduct Check	74436-Bing-Wu YXJ-2.png
Scientific Editor Work List	74436-Scientific editor work list.pdf